Omanta Health maps patient records and genomics to potential therapies
The YC S26 entrant says its system combines longitudinal records, personal genomics and scientific literature to map disease drivers and therapies.
By Ryan Merket · Published
Why it matters
Omanta Health is betting that patient records, genomics and medical literature can become one decision layer. Clinical validation and a clearly defined user will determine whether that layer is useful in care.
Omanta Health (@Omantahealth) introduced a personalized medical research system in a launch post that says it will combine a patient's full medical record, genomic data and current scientific evidence to identify the molecular mechanisms driving disease.
The product, also called Omanta, is intended to map those findings against existing and emerging therapies, according to the launch announcement. That description places Omanta Health in precision medicine and clinical decision support, where useful software must reconcile fragmented records, interpret genetic variants and keep pace with a changing body of medical literature.
Omanta Health identifies itself as a member of Y Combinator's Summer 2026 batch. Under Y Combinator's published standard deal, accepted companies receive $500,000 through two investments: $125,000 for 7% and $375,000 through an uncapped safe with a most-favored-nation provision. Omanta Health has not announced separate financing in its launch materials.
A broad precision-medicine pitch
Omanta Health is proposing a wider data layer than a genomic test alone. A medical record can contain years of diagnoses, laboratory results, medications, imaging reports, pathology and treatment responses. Genomic data adds another set of signals, while scientific papers and clinical evidence provide the basis for connecting those signals to possible interventions.
Bringing those sources into one system is technically plausible. Producing findings that physicians or patients can rely on requires a harder set of proofs: accurate record ingestion, transparent evidence citations, clinically sound variant interpretation and a clear method for ranking therapies when studies conflict or apply only to narrow patient populations.
Existing products show how companies have narrowed that task. Genomate Health focuses on precision oncology, combining molecular profiles with computational reasoning to rank treatment options for physicians. The company explicitly describes its report as clinical decision support that must be interpreted by qualified healthcare professionals.
Academic researchers are pursuing a similarly data-intensive approach. Stanford and UCSF's Project IMPACT-AI is developing models that combine electronic medical records, pathology, radiology and molecular profiles for individualized cancer treatment. Foundation Medicine has built its precision-medicine business around genomic profiling, clinical interpretation and companion diagnostics.
Omanta Health's stated scope reaches beyond oncology and beyond testing. The launch language refers broadly to disease and promises to map emerging therapies alongside existing options. That breadth could make Omanta useful across specialty care, where clinicians often have to assemble a patient's history and relevant research manually. It also increases the burden of validation because the quality, maturity and clinical relevance of evidence vary sharply across diseases.
The product boundary will shape the business
The central product choice is whether Omanta operates as a research workspace for clinicians or gives patients treatment guidance directly. A physician-facing evidence tool, a patient research service and software embedded in a hospital record system require different interfaces, sales channels and safeguards.
That distinction also affects regulatory exposure in the United States. The Food and Drug Administration's January 2026 clinical decision support guidance explains which clinician-facing support functions may fall outside the medical-device definition and notes that existing digital-health policies continue to apply to software functions that qualify as devices, including products intended for patients or caregivers.
Omanta Health's therapy-mapping claim makes explainability central to the product. A useful output would need to show which records, variants and studies produced a conclusion, while distinguishing approved treatments from experimental approaches and early research. A generated list without that provenance would leave clinicians to repeat the underlying research before using it.
Omanta Health has chosen the widest version of the personalized-medicine proposition: one research layer spanning the patient record, molecular biology and therapeutic evidence. The next proof is narrower and more consequential. Omanta Health must show who will use the system, which diseases it handles first and how its molecular and therapy findings are evaluated against clinical judgment.